EHA: AbbVie, Roche cement Venclexta's place in AML with survival win

AbbVie and Roche’s Venclexta has struggled to significantly prolong acute myeloid leukemia (AML) patients’ lives when coupled with a certain type of chemo. But not azacitidine.

Adding Venclexta to azacitidine slashed the risk of death by 34% among previously untreated patients, the partners said Saturday at the European Hematology Association’s virtual annual congress.